Skip to content

Medical Mutual

Does Medical Mutual cover Zepbound?

It depends on your benefits. Medical Mutual covers Zepbound for weight loss only when your plan includes that benefit and the policy requirements are met.

Policy document

  • Employer: Depends on your plan's benefit. See the qualification pathways below.

Earliest policy review June 10, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

Qualification pathways

You can qualify through any one of these.

Adult Initial Therapy (age ≥ 18)

All of:

  • Patient is ≥ 18 years of age
  • Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
  • Zepbound will be used concomitantly with a behavioral modification program and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Plus any one of:

  • At baseline, patient had a BMI ≥ 32 kg/m2
  • At baseline, patient had a BMI ≥ 27 kg/m2 AND at least TWO of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, OSA, CVD, knee osteoarthritis, asthma, COPD, NASH/NAFLD, PCOS, or CAD

Adult Continuation Therapy (age ≥ 18)

All of:

  • Patient is ≥ 18 years of age
  • Patient has lost ≥ 5% of baseline body weight
  • Zepbound will be used concomitantly with a behavioral modification program and a reduced-calorie diet
  • Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology
  • Patient has completed at least 8 months of initial therapy OR is within initial approval period

Plus any one of:

  • At baseline, patient had a BMI ≥ 32 kg/m2
  • At baseline, patient had a BMI ≥ 27 kg/m2 AND at least TWO weight-related comorbidities

Documentation to bring

  • Documentation of baseline BMI (≥ 32 kg/m2, OR ≥ 27 kg/m2 with at least two qualifying comorbidities) prior to any GLP-1 or GLP-1/GIP agonist use
  • Documentation of at least 3-month trial of behavioral modification and dietary restriction
  • For BMI ≥ 27 pathway: documentation of at least two qualifying weight-related comorbidities
  • For continuation: documentation of ≥ 5% baseline body weight loss
  • For continuation: prescriber attestation of ability to tolerate maintenance dose (5 mg, 10 mg, or 15 mg once weekly) or confirmation of ongoing dose titration toward 10 mg or 15 mg once weekly
  • Prescriber specialty credentials (to confirm not in excluded specialty)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • Renewal: Adult: must have lost ≥ 5% of baseline body weight. Patient must be able to tolerate a Zepbound maintenance dose of 5 mg, 10 mg, or 15 mg once weekly for 1-year approval; if still titrating to 10 mg or 15 mg and < 12 consecutive months received, approve for up to 4 months. Baseline BMI eligibility is re-verified at continuation.
  • Renewal: Staying on a maintenance dose of at least 5 mg.

Not covered when

  • Concomitant use with other FDA-approved weight loss medications (e.g., phentermine, benzphetamine, diethylpropion, phendimetrazine, Contrave, Qsymia, orlistat)
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists
  • Prescriber who specializes primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Policy note: Zepbound weight loss indication applies to adults only (no pediatric criteria listed for Zepbound weight loss in this policy). Initial approval is 8 months. Continuation is 1 year if maintenance dose (5, 10, or 15 mg once weekly) is tolerated; up to 4 months if still titrating to 10 or 15 mg and <12 consecutive months completed. The policy notes that 5 mg once weekly should be achievable within the 8-month initial period. Baseline BMI refers to baseline prior to any GLP-1 or GLP-1/GIP agonist use.

verified June 10, 2026 · source: Weight Loss Glucagon Like Peptide1 GLP-1 Agonists · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans. OSA indication falls under this weight loss GLP-1 policy.

Qualification pathways

You can qualify through any one of these.

OSA Initial Therapy (age ≥ 18)

All of:

  • Patient is ≥ 18 years of age
  • Patient has a current BMI ≥ 30 kg/m2
  • Sleep study within the past 1 year showing: diagnosis of moderate to severe OSA AND apnea-hypopnea index (AHI) ≥ 15 events per hour
  • Patient does NOT have central sleep apnea with ≥ 50% central apneas/hypopneas
  • Patient does NOT have Cheyne Stokes respiration
  • Medication will be used concomitantly with behavioral modification and a reduced-calorie diet

OSA Continuation Therapy

All of:

  • Patient is ≥ 18 years of age
  • At baseline (before Zepbound), patient had a BMI ≥ 30 kg/m2
  • Patient has completed ≥ 1 year of therapy with Zepbound
  • Patient has lost ≥ 10% of baseline body weight
  • Prescriber confirms stability in OSA signs or symptoms
  • Medication will be used concomitantly with behavioral modifications and a reduced-calorie diet

Documentation to bring

  • Documentation of current BMI ≥ 30 kg/m2
  • Sleep study results within the past 1 year documenting: moderate to severe OSA diagnosis AND AHI ≥ 15 events per hour
  • Documentation confirming absence of central sleep apnea (≥ 50% central apneas/hypopneas) and absence of Cheyne Stokes respiration
  • For continuation: documentation of baseline BMI ≥ 30 kg/m2 prior to Zepbound
  • For continuation: documentation of ≥ 10% baseline body weight loss
  • For continuation: prescriber attestation of stability in OSA signs or symptoms

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Patient must have completed ≥ 1 year of therapy with Zepbound AND lost ≥ 10% of baseline body weight AND have stability in OSA signs or symptoms (e.g., snoring, excessive daytime sleepiness, fatigue) per prescriber attestation.

Not covered when

  • Central sleep apnea with percent of central apneas/hypopneas ≥ 50%
  • Cheyne Stokes respiration
  • Concomitant use with other FDA-approved weight loss medications
  • Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists

Policy note: Sleep study must be within the past 1 year for initial approval. Moderate OSA defined as AHI ≥ 15 events/hour; severe OSA defined as AHI ≥ 30 events/hour. Initial and continuation approval both for 1 year. No PAP/CPAP trial requirement stated. Continuation requires both ≥ 10% body weight loss AND OSA symptom stability — higher weight loss threshold than the weight loss indication (10% vs 5%). The OSA indication is subject to the same weight loss drug benefit restriction as all other indications in this policy.

verified June 10, 2026 · source: Weight Loss Glucagon Like Peptide1 GLP-1 Agonists · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

Medical Mutual has separate Zepbound policies that don't depend on that benefit:

Questions people ask
Does Medical Mutual cover Zepbound?
It depends on your benefits. Medical Mutual covers Zepbound for weight loss only when your plan includes that benefit and the policy requirements are met.
How long does a Zepbound approval last with Medical Mutual?
Weight Loss — Applies to Employer plans. Initial approval: 8 months. Renewal: every 12 months. Obstructive Sleep Apnea (OSA) — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.
What does Medical Mutual require to renew Zepbound?
Weight Loss — Applies to Employer plans. Adult: must have lost ≥ 5% of baseline body weight. Patient must be able to tolerate a Zepbound maintenance dose of 5 mg, 10 mg, or 15 mg once weekly for 1-year approval; if still titrating to 10 mg or 15 mg and < 12 consecutive months received, approve for up to 4 months. Baseline BMI eligibility is re-verified at continuation. Staying on a maintenance dose of at least 5 mg. Obstructive Sleep Apnea (OSA) — Applies to Employer plans. Patient must have completed ≥ 1 year of therapy with Zepbound AND lost ≥ 10% of baseline body weight AND have stability in OSA signs or symptoms (e.g., snoring, excessive daytime sleepiness, fatigue) per prescriber attestation.
How current is this information?
The oldest review date among the policies on this page is June 10, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Medical Mutual: Ozempic, Wegovy

Zepbound under other plans: Elevance Health, Ohio Medicaid, Alabama Medicaid, California Medicaid, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid, Illinois Medicaid

All insurance plans · All medications

Summary of Medical Mutual's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.